title: The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.
abstract: We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease. Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy. The glomerulopathy was induced by seven serial injections of PAN over 12 wk. Experimental animals (n = 6) received rhIGF-I, 400 micrograms/d, whereas control rats (n = 6) received the vehicle. rhIGF-I improved weight gain by 14% (p < 0.05), without altering hematocrit or blood pressure in rats with renal disease. Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy. After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05. The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content. In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA. In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors. We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.
authors.affiliation: Department of Pediatrics (Division of Nephrology), Long Island Campus for the Albert Einstein College of Medicine, New York, 11040, USA.
authors.forename: H
authors.initials: H
authors.lastname: Trachtman
authors.forename: J
authors.initials: J
authors.lastname: Maesaka
authors.forename: S
authors.initials: S
authors.lastname: Futterweit
authors.forename: C
authors.initials: C
authors.lastname: Ma
authors.forename: E
authors.initials: E
authors.lastname: Valderrama
authors.forename: J C
authors.initials: JC
authors.lastname: Chan
authors.forename: W
authors.initials: W
authors.lastname: Chan
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D002908:Chronic Disease; D004195:Disease Models, Animal; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology*; D007674:Kidney Diseases / Q000097:blood / Q000378:metabolism / Q000503:physiopathology* / Q000652:urine; D007678:Kidney Glomerulus; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011507:Proteinuria / Q000378:metabolism; D011692:Puromycin Aminonucleoside; D051381:Rats; D017207:Rats, Sprague-Dawley; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D015430:Weight Gain
chemical_list: D001786:Blood Glucose; D007328:Insulin; D011994:Recombinant Proteins; D008315:Malondialdehyde; D011692:Puromycin Aminonucleoside; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1